MedTrace Logo

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

NCT04329806 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to study the role of sympathetic mechanisms involved in chronic regulation of cardiovascular and metabolic abnormalities seen in obesity. The investigators will study the effects chronic sympathetic inhibition on insulin sensitivity, inflammation and endothelial function in obese hypertensive human subjects.

Conditions

  • Obesity-Associated Insulin Resistance

Interventions

DRUG

Moxonidine 0.2 MG

Moxonidine 0.2 MG twice daily

DRUG

Amlodipine 5 MG

Amlodipine 5 MG twice daily

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Italo Biaggioni

    lead OTHER

Principal Investigators

  • Italo Biaggioni, MD · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2022-07-27
Completion
2022-07-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04329806 on ClinicalTrials.gov